Comparison of Heparin Anti-Xa Activity From Central Venous Catheter Samples Using a 5 mL Syringe Flush or a Vacuum Tube Flush Versus Peripheral Vein Samples in ICU Patients
NCT ID: NCT07183605
Last Updated: 2025-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2025-09-22
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To evaluate the reliability of central venous blood sampling, the study will compare anti-Xa activity levels obtained simultaneously from two different types of blood draws: one from a peripheral vein (reference method), and the other from the central line using one of two flushing techniques.
The two central flushing techniques being studied are:
* A 5 mL syringe flush performed over 5 seconds, followed by blood collection.
* A vacuum tube flush that draws and discards 5 mL of blood, followed by blood collection.
Each patient will undergo four pairs of simultaneous blood draws, using both central techniques in a randomized sequence. The main objective is to assess whether the anti-Xa levels from central samples are equivalent to those from peripheral vein puncture, with a predefined margin of equivalence of ±0.05 IU/mL.
Findings from this study may support the use of central venous catheters for routine anti-Xa monitoring in ICU patients, potentially avoiding painful or technically difficult peripheral vein punctures.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Venous Thrombosis After Removal of Central Venous Catheter
NCT06349291
"Follow-up of Midlines Placed Outside the Intensive Care Unit: What Side Effects? An Observational Study"
NCT04131088
The Central Venous Catheter Related Complications in Critically Ill Patients
NCT03841240
Complications and Failure of Centrally Inserted Central Catheters in Cardiac Surgical Patients
NCT07138690
Ultrasound-Guided Peripheral Intravenous Access by Critical Nurses.
NCT02285712
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The reference method for anti-Xa monitoring involves blood sampling by peripheral vascular puncture. However, in ICU patients, peripheral access may be challenging or painful, and central venous catheters are often available and already used for UFH infusion. Sampling from these central lines could be a convenient alternative, but residual heparin in the catheter may contaminate the sample, leading to falsely elevated anti-Xa results.
The CASSANDRA study (Central catheter Anti-Xa Sampling Study for Accurate aNalysis and Reliable Dosage Assessment) is a prospective, monocentric, comparative study designed to assess whether anti-Xa activity levels obtained from central venous catheter samples are equivalent to those from peripheral vein samples.
To be eligible for inclusion, patients must already have a central venous catheter in place and require continuous intravenous unfractionated heparin administration through the distal lumen of the central venous catheter.
A three-way stopcock will be placed upstream of the infusion tubing to allow temporary interruption of UFH infusion during sampling.
Two catheter flushing techniques will be compared:
* Method A: A 5 mL flush performed with a syringe over 5 seconds.
* Method B: A 5 mL flush using a vacuum tube (standard discard tube).
For each patient, four pairs of simultaneous blood samples will be collected, according to a randomized sequence alternating between methods A and B. In each pair, one sample will be drawn from the central venous catheter and the other from a fresh peripheral vein puncture (reference). All anti-Xa assays will be performed, but only the results from peripheral vein samples (reference method) will be made available to clinicians. Anti-Xa results from central venous catheter samples will remain blinded to the clinical team to avoid influencing patient management.
The primary outcome is the absolute difference in anti-Xa activity between central venous catheter samples (either method) and peripheral samples. Equivalence is defined as a mean difference not exceeding 0.05 IU/mL. Secondary outcomes include Bland-Altman agreement limits between each central method and the peripheral reference.
Results of this study may support the safe use of central venous sampling for routine anti-Xa monitoring in ICU patients, provided an appropriate flushing method is used.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence A, B, A, B
First and third samples with syringe flush; second and fourth with vacuum tube flush
catheter flushing techniques
Two catheter flushing techniques will be compared:
* Method A: A 5 mL flush performed with a syringe over 5 seconds.
* Method B: A 5 mL flush using a vacuum tube (standard discard tube).
Sequence A, B, B, A
First and fourth samples with syringe flush; second and third with vacuum tube flush
catheter flushing techniques
Two catheter flushing techniques will be compared:
* Method A: A 5 mL flush performed with a syringe over 5 seconds.
* Method B: A 5 mL flush using a vacuum tube (standard discard tube).
Sequence B, A, B, A
Second and fourth samples with syringe flush; first and third with vacuum tube flush
catheter flushing techniques
Two catheter flushing techniques will be compared:
* Method A: A 5 mL flush performed with a syringe over 5 seconds.
* Method B: A 5 mL flush using a vacuum tube (standard discard tube).
Sequence B, A, A, B
Second and third samples with syringe flush; first and fourth with vacuum tube flush
catheter flushing techniques
Two catheter flushing techniques will be compared:
* Method A: A 5 mL flush performed with a syringe over 5 seconds.
* Method B: A 5 mL flush using a vacuum tube (standard discard tube).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
catheter flushing techniques
Two catheter flushing techniques will be compared:
* Method A: A 5 mL flush performed with a syringe over 5 seconds.
* Method B: A 5 mL flush using a vacuum tube (standard discard tube).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years of age or older
* Hospitalized in intensive care medicine
* Having a central venous catheter with at least three lumens (internal jugular, subclavian or femoral) already in place
* Receiving continuous intravenous unfractionned heparin, with target Anti-Xa activity between 0.3 and 0.7 IU/ml.
Exclusion Criteria
* Person under court protection
* Person deprived of liberty
* Person not affiliated to the French social security
* Pregnant or breast-feeding woman
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Régional d'Orléans
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gregoire MULLER, Dr
Role: PRINCIPAL_INVESTIGATOR
CHU Orléans
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Orleans
Orléans, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHUO-2024-27
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.